A5071847071- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Extracellular vesicles in disease
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Hematological disorders and diagnostics
- Erythropoietin and Anemia Treatment
- Bone and Joint Diseases
- Mesenchymal stem cell research
- Blood disorders and treatments
- Erythrocyte Function and Pathophysiology
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Asphalt Pavement Performance Evaluation
- Structural Engineering and Vibration Analysis
- Platelet Disorders and Treatments
- HER2/EGFR in Cancer Research
- T-cell and B-cell Immunology
- Polyomavirus and related diseases
- Cancer Genomics and Diagnostics
- Sepsis Diagnosis and Treatment
- Infrastructure Maintenance and Monitoring
- S100 Proteins and Annexins
Université Grenoble Alpes
2016-2025
Centre Hospitalier Universitaire de Grenoble
2016-2025
Centre Léon Bérard
2023-2024
Centre National de la Recherche Scientifique
2014-2023
Inserm
2018-2023
Institut pour l'avancée des biosciences
2018-2022
Institut de Biosciences et Biotechnologies
2018
Institut polytechnique de Grenoble
2017
Translational Innovation in Medicine and Complexity
2017
Hôpital Lariboisière
2014
<title>Abstract</title> Chronic graft versus host disease is a major cause of morbidity after allogeneic haematopoietic cell transplantation. Belumosudil has recently been approved for the treatment cGVHD refractory two lines treatment. However, few data are available to evaluate its efficacy and safety in real life. 68 patients with received belumosudil through compassionate access program France. The median follow-up was 337 days from initiation. Eighty-two percent had severe three organs...
PPM1D, a central regulator of the DNA damage response, is commonly mutated in therapy-related clonal hematopoiesis (CH), acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). PPM1D mutations have been shown to expand under selective pressure DNA-damaging chemotherapy. However, whether promote development hematologic malignancies remains unclear. We characterized clinical genomic profiles 112 PPM1D-mutated patients across spectrum disorders using combination bulk single-cell...
Anemia is a frequent cytopenia in myelodysplastic syndromes (MDS) and most patients require red blood cell transfusion resulting iron overload (IO). Deferasirox (DFX) has become the standard treatment of IO MDS it displays positive effects on erythropoiesis. In low risk samples, mechanisms improving erythropoiesis after DFX remain unclear. Herein, we addressed this question by using liquid cultures with erythroid precursors treated dose (3μM), which corresponds to 5 mg/kg/day, an unusual...
Objectives Cytomegalovirus (CMV) is frequently detected in lung and/or blood samples of patients with Pneumocystis jirovecii pneumonia (PJP), although this co-detection not precisely understood. We aimed to determine whether PJP was more severe case CMV detection. Methods retrospectively included all a diagnosis between 2009 and 2020 our centre measure viral load bronchoalveolar lavage (BAL). severity assessed by the requirement for intensive care unit (ICU) admission. Results The median age...
The value of pretransplant splenectomy in patients with myelofibrosis (MF) is subject to debate, since the procedure may preclude subsequent allogeneic hematopoietic cell transplantation (allo-HCT). To determine impact on incidence allo-HCT, we conducted a comprehensive retrospective study all MF for whom an unrelated donor search had been initiated via French bone marrow registry (RFGM) between 1 January 2008 and 2017. Additional data were collected from patients' medical files database...
Erythropoiesis-stimulating agents are generally the first line of treatment anemia in patients with lower-risk myelodysplastic syndrome. We prospectively investigated predictive value somatic mutations, and biomarkers ineffective erythropoiesis including flow cytometry RED score, serum growth-differentiation factor-15, hepcidin levels. Inclusion criteria were no prior erythropoiesis-stimulating agents, low- or intermediate-1-risk syndrome according to International Prognostic Scoring System,...
Summary Despite a moderate prevalence in low‐risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia (CMML), thrombocytopenia remains risk of severe bleeding therapeutic options are still limited. There only few studies with eltrombopag (ELT), thrombopoietin receptor agonist, those patients. In this retrospective multicentre study, ELT was used 50 patients MDS 11 CMML, no excess marrow blasts platelet counts <50 × 10 9 /l ‘real‐life’ situation. Platelet response occurred...
Acute graft-versus-host disease (aGVHD) still remains the main cause of morbidity and mortality after allogeneic stem cell transplantation. Moreover, patients who did not respond to first-line treatment with glucocorticosteroids have a very poor outcome. Some studies suggested that alemtuzumab (a humanized monoclonal antibody against CD52 antigen) might be effective for refractory aGVHD. Here we report single-center experience in gastrointestinal From September 2009 April 2012 at Grenoble...
We report 3 consecutive episodes of invasive aspergillosis in a single hematopoietic stem cell transplant patient successively attributed to TR(34) /L98H azole-resistant Aspergillus fumigatus and first occurrence Emericella sublata infection. This case illustrates potential selection resistant molds during antifungal therapy hematological patient.
Abstract Chronic myelomonocytic leukemia (CMML) is a myeloid hematological malignancy with overlapping features of myelodysplastic syndromes (MDSs) and myeloproliferative neoplasms (MPNs). The knowledge the role tumor microenvironment (TME), particularly mesenchymal stromal cells (MSCs), in MDS pathogenesis increasing. Generally, cancer associated procoagulant state participating development. Monocytes release procoagulant, tissue factor (TF)–bearing microparticles. We hypothesized that MSCs...
// Mathieu Meunier 1, 2, * , Charles Dussiau 3, Natacha Mauz 2 Anne Sophie Alary 3 Christine Lefebvre 4 Gautier Szymanski Mylène Pezet 5 Françoise Blanquet 6 Olivier Kosmider and Park 1 University Clinic of Hematology, CHU Grenoble Alpes, Grenoble, France TIMC-Therex, UMR 5525 CNRS, Alpes University, Hématologie Biologique, Hôpital Cochin, Assistance Publique-Hôpitaux De Paris, Laboratory Onco-Genetic Immunology, Biology Pathology Institute, Optical...
Therapy-related myelodysplastic syndrome (t-MDS) after autologous stem cell transplantation (ASCT) is a rare complication with no curative option. Allogeneic hematopoietic (allo-HSCT) may be considered for eligible patients and has been understudied in t-MDS. We report 47 consecutive t-MDS an ASCT who underwent allo-HSCT median age of 58 years (range, 30 to 71 years) at follow-up 22 months 0.7 107). The overall survival (OS) was 6.9 (95% confidence interval [CI], 0 19 months). OS rates were...